Unexpectedly Rapid Onset of Severe Sarcopenia in an Elderly Diabetic Man following SGLT2i Administration: A Case Report.
Paulina CzarneckaKinga CzarneckaOlga TroninaPublished in: Journal of clinical medicine (2024)
Sarcopenia is characterized by the progressive loss of muscle mass, strength, and function and poses a significant health challenge among people with diabetes. Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are the backbone of type 2 diabetes treatment. The interplay between SGLT2is and sarcopenia is an area of active research with inconclusive results. This article presents an unexpectedly rapid weight reduction, along with physical performance deterioration, in an elderly patient with type 2 diabetes, which led to treatment discontinuation. A bioelectrical impedance analysis confirmed severe sarcopenia development. Until more data are available, sarcopenia and body composition screening and monitoring may be warranted whenever SGLT2is are prescribed.
Keyphrases
- body composition
- community dwelling
- skeletal muscle
- type diabetes
- resistance training
- physical activity
- mental health
- cardiovascular disease
- healthcare
- early onset
- body mass index
- middle aged
- multiple sclerosis
- magnetic resonance
- weight loss
- risk assessment
- magnetic resonance imaging
- insulin resistance
- combination therapy
- machine learning
- high intensity
- glycemic control
- replacement therapy
- quantum dots
- deep learning
- drug induced
- contrast enhanced